Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

EBV Latency III-Transformed B Cells Are Inducers of Conventional and Unconventional Regulatory T Cells in a PD-L1-Dependent Manner.

Auclair H, Ouk-Martin C, Roland L, Santa P, Al Mohamad H, Faumont N, Feuillard J, Jayat-Vignoles C.

J Immunol. 2019 Sep 15;203(6):1665-1674. doi: 10.4049/jimmunol.1801420. Epub 2019 Aug 21.

2.

Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.

Vincent-Fabert C, Roland L, Zimber-Strobl U, Feuillard J, Faumont N.

Cell Commun Signal. 2019 Aug 5;17(1):89. doi: 10.1186/s12964-019-0391-x.

3.

Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells.

Vincent-Fabert C, Soubeyran I, Velasco V, Parrens M, Jeannet R, Lereclus E, Gachard N, Feuillard J, Faumont N.

Cell Mol Immunol. 2019 Jun;16(6):621-624. doi: 10.1038/s41423-019-0228-y. Epub 2019 Apr 9. No abstract available.

PMID:
30967638
4.

Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.

Guénot C, Lacombe F, Allou K, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Maynadié M, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC; Groupe d’Etude Immunologique des Leucémies (GEIL).

Leukemia. 2019 Jul;33(7):1814-1816. doi: 10.1038/s41375-019-0393-0. Epub 2019 Feb 5. No abstract available.

PMID:
30723257
5.

Reproducing indolent B-cell lymphoma transformation with T-cell immunosuppression in LMP1/CD40-expressing mice.

Vincent-Fabert C, Saintamand A, David A, Alizadeh M, Boyer F, Arnaud N, Zimber-Strobl U, Feuillard J, Faumont N.

Cell Mol Immunol. 2019 Apr;16(4):412-414. doi: 10.1038/s41423-018-0197-6. Epub 2019 Jan 11. No abstract available.

PMID:
30635651
6.

Adult Bone Marrow Three-Dimensional Phenotypic Landscape of B-Cell Differentiation.

Carrion C, Guérin E, Gachard N, le Guyader A, Giraut S, Feuillard J.

Cytometry B Clin Cytom. 2019 Jan;96(1):30-38. doi: 10.1002/cyto.b.21747. Epub 2018 Nov 18.

PMID:
30450798
7.

Immature Granulocytes: A Risk Factor of Infection after Cardiac Surgery.

Daix T, Guérin E, Tavernier E, Marsaud JP, Hacan A, Gauthier F, Piccardo A, Vignon P, Feuillard J, François B.

Cytometry B Clin Cytom. 2018 Nov;94(6):887-894. doi: 10.1002/cyto.b.21739. Epub 2018 Oct 16.

PMID:
30328273
8.

Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.

Lamaa D, Lin HP, Zig L, Bauvais C, Bollot G, Bignon J, Levaique H, Pamlard O, Dubois J, Ouaissi M, Souce M, Kasselouri A, Saller F, Borgel D, Jayat-Vignoles C, Al-Mouhammad H, Feuillard J, Benihoud K, Alami M, Hamze A.

J Med Chem. 2018 Aug 9;61(15):6574-6591. doi: 10.1021/acs.jmedchem.8b00050. Epub 2018 Jul 26.

PMID:
30004697
9.

Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.

Chauzeix J, Laforêt MP, Deveza M, Crowther L, Marcellaud E, Derouault P, Lia AS, Boyer F, Bargues N, Olombel G, Jaccard A, Feuillard J, Gachard N, Rizzo D.

Cancer Med. 2018 Jun;7(6):2621-2628. doi: 10.1002/cam4.1510. Epub 2018 May 9.

10.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.

Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P.

Leukemia. 2018 Sep;32(9):2066-2069. doi: 10.1038/s41375-018-0137-6. Epub 2018 Apr 18. No abstract available.

PMID:
29740159
11.

Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening.

Daix T, Guerin E, Tavernier E, Mercier E, Gissot V, Hérault O, Mira JP, Dumas F, Chapuis N, Guitton C, Béné MC, Quenot JP, Tissier C, Guy J, Piton G, Roggy A, Muller G, Legac É, de Prost N, Khellaf M, Wagner-Ballon O, Coudroy R, Dindinaud E, Uhel F, Roussel M, Lafon T, Jeannet R, Vargas F, Fleureau C, Roux M, Allou K, Vignon P, Feuillard J, François B; Septiflux Trial Group.

Chest. 2018 Sep;154(3):617-627. doi: 10.1016/j.chest.2018.03.058. Epub 2018 Apr 26.

PMID:
29705219
12.

Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.

Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Jouault H, Lepelley P, Maynadié M, Solly F, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC; Groupe d'Etude Immunologique des Leucémies (GEIL).

Hematol Oncol. 2018 Apr;36(2):422-428. doi: 10.1002/hon.2488. Epub 2017 Dec 7.

PMID:
29218734
13.

Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type.

Pham-Ledard A, Prochazkova-Carlotti M, Deveza M, Laforet MP, Beylot-Barry M, Vergier B, Parrens M, Feuillard J, Merlio JP, Gachard N.

J Dermatol Sci. 2017 Nov;88(2):238-246. doi: 10.1016/j.jdermsci.2017.07.008. Epub 2017 Jul 26.

PMID:
28838616
14.

c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells.

David A, Arnaud N, Fradet M, Lascaux H, Ouk-Martin C, Gachard N, Zimber-Strobl U, Feuillard J, Faumont N.

Haematologica. 2017 May;102(5):883-894. doi: 10.3324/haematol.2016.156281. Epub 2017 Feb 23.

15.

A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?

Troadec E, Dobbelstein S, Bertrand P, Faumont N, Trimoreau F, Touati M, Chauzeix J, Petit B, Bordessoule D, Feuillard J, Bastard C, Gachard N.

Leukemia. 2017 Feb;31(2):514-517. doi: 10.1038/leu.2016.304. Epub 2016 Oct 31. No abstract available.

16.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

17.

Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas.

Rizzo D, Viailly PJ, Mareschal S, Bohers E, Picquenot JM, Penther D, Dubois S, Marchand V, Bertrand P, Maingonnat C, Etancelin P, Feuillard J, Bastard C, Tilly H, Jardin F, Ruminy P.

Am J Hematol. 2017 Jan;92(1):68-76. doi: 10.1002/ajh.24584.

18.

Clonal deleted latent membrane protein 1 variants of Epstein-Barr virus are predominant in European extranodal NK/T lymphomas and disappear during successful treatment.

Halabi MA, Jaccard A, Moulinas R, Bahri R, Al Mouhammad H, Mammari N, Feuillard J, Ranger-Rogez S.

Int J Cancer. 2016 Aug 15;139(4):793-802. doi: 10.1002/ijc.30128. Epub 2016 Apr 29.

19.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. No abstract available.

PMID:
26929274
20.

Enhancer of zeste acts as a major developmental regulator of Ciona intestinalis embryogenesis.

Le Goff E, Martinand-Mari C, Martin M, Feuillard J, Boublik Y, Godefroy N, Mangeat P, Baghdiguian S, Cavalli G.

Biol Open. 2015 Aug 14;4(9):1109-21. doi: 10.1242/bio.010835.

21.

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Bardet V, Wagner-Ballon O, Guy J, Morvan C, Debord C, Trimoreau F, Benayoun E, Chapuis N, Freynet N, Rossi C, Mathis S, Gourin MP, Toma A, Béné MC, Feuillard J, Guérin E; Groupe Francophone des Myélodysplasies (GFM); Groupe d’Etude Immunologique des Leucémies (GEIL).

Haematologica. 2015 Apr;100(4):472-8. doi: 10.3324/haematol.2014.112755. Epub 2015 Jan 30.

22.

IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Rizzo D, Chauzeix J, Trimoreau F, Woillard JB, Genevieve F, Bouvier A, Labrousse J, Poli C, Guerin E, Dmytruk N, Remenieras L, Feuillard J, Gachard N.

Leukemia. 2015 Feb;29(2):337-45. doi: 10.1038/leu.2014.198. Epub 2014 Jun 19.

PMID:
24943833
23.

Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration*.

Guérin E, Orabona M, Raquil MA, Giraudeau B, Bellier R, Gibot S, Béné MC, Lacombe F, Droin N, Solary E, Vignon P, Feuillard J, François B.

Crit Care Med. 2014 Sep;42(9):2007-18. doi: 10.1097/CCM.0000000000000344.

PMID:
24942511
24.

Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases.

Farhat M, Poissonnier A, Hamze A, Ouk-Martin C, Brion JD, Alami M, Feuillard J, Jayat-Vignoles C.

Cell Death Dis. 2014 May 1;5:e1201. doi: 10.1038/cddis.2014.150.

25.

Identification of a human splenic marginal zone B cell precursor with NOTCH2-dependent differentiation properties.

Descatoire M, Weller S, Irtan S, Sarnacki S, Feuillard J, Storck S, Guiochon-Mantel A, Bouligand J, Morali A, Cohen J, Jacquemin E, Iascone M, Bole-Feysot C, Cagnard N, Weill JC, Reynaud CA.

J Exp Med. 2014 May 5;211(5):987-1000. doi: 10.1084/jem.20132203. Epub 2014 Apr 14. Erratum in: J Exp Med. 2014 May 5;21(5):1005. Sarnacki, Sabine [added].

26.

RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

Chanut A, Duguet F, Marfak A, David A, Petit B, Parrens M, Durand-Panteix S, Boulin-Deveza M, Gachard N, Youlyouz-Marfak I, Bordessoule D, Feuillard J, Faumont N.

Leukemia. 2014 Apr;28(4):871-9. doi: 10.1038/leu.2013.274. Epub 2013 Sep 23.

PMID:
24056880
27.

Very low levels of surface CD45 reflect CLL cell fragility, are inversely correlated with trisomy 12 and are associated with increased treatment-free survival.

Rizzo D, Lotay A, Gachard N, Marfak I, Faucher JL, Trimoreau F, Guérin E, Bordessoule D, Jaccard A, Feuillard J.

Am J Hematol. 2013 Sep;88(9):747-53. doi: 10.1002/ajh.23494. Epub 2013 Jul 23.

28.

Design and feasibility of a novel, rapid, and simple fluorescence 26-plex rt-PCR assay for simultaneous detection of 24 fusion transcripts in adult acute myeloid leukemia.

Laforêt MP, Turlure P, Lippert E, Cornillet-Lefebvre P, Pigneux A, Pradeau R, Feuillard J, Gachard N.

J Mol Diagn. 2013 Mar;15(2):186-95. doi: 10.1016/j.jmoldx.2012.11.004. Epub 2013 Jan 11.

PMID:
23318495
29.

T/B ratio does not reflect levels of ZAP70 expression in clonal CLL B-cells due to ZAP70 overexpression in patient T-cells.

Rizzo D, Bouvier G, Youlyouz-Marfak I, Guerin E, Trimoreau F, Bordessoule D, Jaccard A, Gachard N, Feuillard J.

Cytometry B Clin Cytom. 2013 Mar;84(2):125-32. doi: 10.1002/cyto.b.21055. Epub 2012 Dec 6.

30.

IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.

Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A, Rizzo D, Devesa M, Delage-Corre M, Coste V, Laforêt MP, de Mascarel A, Merlio JP, Bouabdhalla K, Milpied N, Soubeyran P, Schmitt A, Bordessoule D, Cogné M, Feuillard J.

Leukemia. 2013 Jan;27(1):183-9. doi: 10.1038/leu.2012.257. Epub 2012 Sep 4.

PMID:
22944768
31.

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM.

Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. Review.

PMID:
22916713
32.

B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels.

Durand-Panteix S, Farhat M, Youlyouz-Marfak I, Rouaud P, Ouk-Martin C, David A, Faumont N, Feuillard J, Jayat-Vignoles C.

J Immunol. 2012 Jul 1;189(1):181-90. doi: 10.4049/jimmunol.1102277. Epub 2012 Jun 1.

33.

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.

Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA.

Leukemia. 2012 Jul;26(7):1730-41. doi: 10.1038/leu.2012.30. Epub 2012 Feb 6.

PMID:
22307178
34.

Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells.

Ndour PA, Brocqueville G, Ouk TS, Goormachtigh G, Morales O, Mougel A, Bertout J, Melnyk O, Fafeur V, Feuillard J, Coll J, Adriaenssens E.

J Virol. 2012 Apr;86(7):3934-43. doi: 10.1128/JVI.05747-11. Epub 2012 Jan 18.

35.

Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.

Durrieu F, Geneviève F, Arnoulet C, Brumpt C, Capiod JC, Degenne M, Feuillard J, Garand R, Kara-Terki A, Kulhein E, Maynadié M, Ochoa-Noguera ME, Plesa A, Roussel M, Eghbali H, Truchan-Graczyk M, de Carvalho Bittencourt M, Feugier P, Béné MC.

Cytometry B Clin Cytom. 2011 Nov;80(6):346-53. doi: 10.1002/cyto.b.20613. Epub 2011 Oct 4.

36.

A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.

Frébet E, Abraham J, Geneviève F, Lepelley P, Daliphard S, Bardet V, Amsellem S, Guy J, Mullier F, Durrieu F, Venon MD, Leleu X, Jaccard A, Faucher JL, Béné MC, Feuillard J; GEIL Groupe d'Etude Immunologique des Leucémies Study Group.

Cytometry B Clin Cytom. 2011 May;80(3):176-85. doi: 10.1002/cyto.b.20581. Epub 2010 Dec 10.

37.
38.

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup.

Blood. 2011 Feb 10;117(6):1834-9. doi: 10.1182/blood-2010-09-307454. Epub 2010 Dec 1.

PMID:
21123825
39.

Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010.

Faure GC, Amsellem S, Arnoulet C, Bardet V, Campos L, De Carvalho-Bittencourt M, de Labarthe A, Eischen A, Feuillard J, Fossat C, Ottou FG, Guérin E, Guy J, Jouault H, Kuhlein E, Lacombe F, Lainey E, Maynadié M, Noguera ME, Roussel M, Solly F, Ballon OW, Béné MC; GEIL workshop.

Immunol Lett. 2011 Jan 30;134(2):145-9. doi: 10.1016/j.imlet.2010.10.008. Epub 2010 Oct 15.

PMID:
20951742
40.

Changes in blood B cell phenotypes and Epstein-Barr virus load in chronically human immunodeficiency virus–infected patients before and after antiretroviral therapy.

Richard Y, Amiel C, Jeantils V, Mestivier D, Portier A, Dhello G, Feuillard J, Creidy R, Nicolas JC, Raphael M.

J Infect Dis. 2010 Nov 1;202(9):1424-34. doi: 10.1086/656479.

PMID:
20874514
41.

Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.

Troutaud D, Petit B, Bellanger C, Marin B, Gourin-Chaury MP, Petit D, Olivrie A, Feuillard J, Jauberteau MO, Bordessoule D.

Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):118-24. doi: 10.3816/CLML.2010.n.016.

PMID:
20371444
42.

Inhibition of tumor necrosis factor-induced phenotypes by short intracellular versions of latent membrane protein-1.

Ndour PA, Ouk TS, Brocqueville G, Mougel A, Vanhecke E, Feuillard J, Coll J, Adriaenssens E.

Cell Signal. 2010 Feb;22(2):303-13. doi: 10.1016/j.cellsig.2009.09.037. Epub 2009 Sep 29.

PMID:
19796681
43.

Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL.

Arnoulet C, Béné MC, Durrieu F, Feuillard J, Fossat C, Husson B, Jouault H, Maynadié M, Lacombe F.

Cytometry B Clin Cytom. 2010 Jan;78(1):4-10. doi: 10.1002/cyto.b.20484.

44.

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, Westers TM.

Haematologica. 2009 Aug;94(8):1124-34. doi: 10.3324/haematol.2009.005801. Epub 2009 Jun 22.

45.

Regulation of DNA polymerase beta by the LMP1 oncoprotein of EBV through the nuclear factor-kappaB pathway.

Faumont N, Le Clorennec C, Teira P, Goormachtigh G, Coll J, Canitrot Y, Cazaux C, Hoffmann JS, Brousset P, Delsol G, Feuillard J, Meggetto F.

Cancer Res. 2009 Jun 15;69(12):5177-85. doi: 10.1158/0008-5472.CAN-08-2866. Epub 2009 Jun 2.

46.

Among 157 marginal zone lymphomas, DBA.44(CD76) expression is restricted to tumour cells infiltrating the red pulp of the spleen with a diffuse architectural pattern.

Petit B, Parrens M, Soubeyran I, Costes-Martineau V, Gachard N, Boulin M, Laurent C, Marfak A, Labrousse F, Bordessoule D, Feuillard J.

Histopathology. 2009 Apr;54(5):626-31. doi: 10.1111/j.1365-2559.2009.03262.x. No abstract available.

PMID:
19413643
47.

Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.

Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadié M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC; GOELAMS and GEIL study.

Br J Haematol. 2009 Jun;145(5):624-36. doi: 10.1111/j.1365-2141.2009.07679.x. Epub 2009 Apr 8.

PMID:
19388928
48.

c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Faumont N, Durand-Panteix S, Schlee M, Grömminger S, Schuhmacher M, Hölzel M, Laux G, Mailhammer R, Rosenwald A, Staudt LM, Bornkamm GW, Feuillard J.

J Virol. 2009 May;83(10):5014-27. doi: 10.1128/JVI.02264-08. Epub 2009 Mar 4.

49.

Comparative analysis of oncogenic properties and nuclear factor-kappaB activity of latent membrane protein 1 natural variants from Hodgkin's lymphoma's Reed-Sternberg cells and normal B-lymphocytes.

Faumont N, Chanut A, Benard A, Cogne N, Delsol G, Feuillard J, Meggetto F.

Haematologica. 2009 Mar;94(3):355-63. doi: 10.3324/haematol.13269. Epub 2009 Feb 11.

50.

Novel function of STAT1beta in B cells: induction of cell death by a mechanism different from that of STAT1alpha.

Najjar I, Schischmanoff PO, Baran-Marszak F, Deglesne PA, Youlyouz-Marfak I, Pampin M, Feuillard J, Bornkamm GW, Chelbi-Alix MK, Fagard R.

J Leukoc Biol. 2008 Dec;84(6):1604-12. doi: 10.1189/jlb.0508287. Epub 2008 Sep 11.

PMID:
18753311

Supplemental Content

Loading ...
Support Center